A drug to treat a life-threatening form of leukemia has gained federal approval.
Tasigna, known generically as nilotinib, won approval to treat chronic and accelerated phase Philadelphia chromosome-positive, chronic myeloid leukemia, a form of the blood cancer. FDA approval is specifically for use in patients who are resistant or intolerant to previous treatment, including with another drug called Gleevec also made by the Swiss pharmaceutical company Novartis AG.
Representatives of the Ministry for Foreign Affairs of the Russian Federation commented on the state of affairs in the Sea of Azov
Russian President Vladimir Putin said at the meeting of the Valdai Discussion Club that Russia will never initiate military actions, including with the use of nuclear weapons